perioperative management of glp-1 agonists Glucagon-Like Peptide-1 Receptor in Care Perioperative Management of GLP-1 RAs

(2020) 69:89LB

Understanding how GLP-1 injections function can help individuals make informed decisions

Discontinuation rates in randomized CV outcome trials As presented in Table 4, some patients randomized to GLP-1 RA treatment discontinued the assigned medication

Tirzepatide should not be used if you have a family history of MTC or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

[DOI] [PubMed] [Google Scholar] 33.Lee Y.-S., Jun H.-S

Cardiovascular benefits The SELECT trial a landmark cardiovascular outcomes study involving over 17,000 participants showed that semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in people with obesity who did not have diabetes